Holen Sie sich die Stockscreener-App
5.17
4.96%
-0.27
Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten
How does Aldeyra Therapeutics Inc. generate profit in a changing economySkyrocketing returns - jammulinksnews.com
What is the risk reward ratio of investing in Aldeyra Therapeutics Inc. stockCapitalize on strategic market trends - jammulinksnews.com
Why is Aldeyra Therapeutics Inc. stock attracting strong analyst attentionDiscover stocks with explosive upside potential - jammulinksnews.com
What are Aldeyra Therapeutics Inc. company’s key revenue driversUnlock high-yield investment opportunities - jammulinksnews.com
How volatile is Aldeyra Therapeutics Inc. stock compared to the marketInvest smarter with expert stock recommendations - jammulinksnews.com
Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA - Ophthalmology Times
Is Aldeyra Therapeutics Inc. a good long term investmentExplosive earning power - PrintWeekIndia
Aldeyra Therapeutics Receives Orphan Designation from the Europe - GuruFocus
What drives Aldeyra Therapeutics Inc. stock priceFree Risk Assessment Services - PrintWeekIndia
What analysts say about Aldeyra Therapeutics Inc. stockExceptional gains - Autocar Professional
EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies - Ophthalmology Times Europe
EMA grants orphan designation for Aldeyra’s eye treatment By Investing.com - Investing.com India
EMA grants orphan designation for Aldeyra’s eye treatment - Investing.com Australia
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa - The Globe and Mail
Published on: 2025-07-23 18:29:07 - Autocar Professional
Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN
FDA accepts Aldeyra's resubmitted reproxalap NDA - Eyes On Eyecare
FDA accepts for review Aldeyra Therapeutics’ resubmitted new drug application for reproxalap - Optometry Times
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
Aldeyra Therapeutics Announces FDA Acceptance for Review of Repr - GuruFocus
Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) - Seeking Alpha
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Lelezard
FDA Accepts Aldeyra’s Reproxalap Application for Review - TipRanks
FDA Reviews Aldeyra's (ALDX) Reproxalap for Dry Eye Disease | AL - GuruFocus
FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug By Investing.com - Investing.com Nigeria
FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug - Investing.com
FDA Reviews Breakthrough Dry Eye Drug: Aldeyra's Reproxalap Could Transform Treatment Landscape - Stock Titan
How Aldeyra Therapeutics Inc. stock performs during market volatilityFree Stock Selection - Newser
Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
why aldeyra therapeutics inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail
Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser
What makes Aldeyra Therapeutics Inc. stock price move sharplyCapital Safe Smart Trades - Newser
Are Medical Stocks Lagging Amgen (AMGN) This Year? - Yahoo Finance
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):